Advertisement

Cellular and Molecular Life Sciences

, Volume 72, Issue 8, pp 1473–1488 | Cite as

Metabolic effects of resveratrol: addressing the controversies

  • Jacob L. Bitterman
  • Jay H. ChungEmail author
Review

Abstract

Resveratrol, a polyphenol found in a number of plant-based foods such as red wine, has received a great deal of attention for its diverse array of healthful effects. Beneficial effects of resveratrol are diverse; they include improvement of mitochondrial function, protection against obesity and obesity-related diseases such as type-2 diabetes, suppression of inflammation and cancer cell growth and protection against cardiovascular dysfunction, just to name a few. Investigations into the metabolic effects of resveratrol are furthest along and now include a number of clinical trials, which have yielded mixed results. There are a number of controversies surrounding resveratrol that have not been resolved. Here, we will review these controversies with particular emphasis on its mechanism of metabolic action and how lessons from resveratrol may help develop therapies that harness the effects of resveratrol but without the undesirable properties of resveratrol.

Keywords

Resveratrol Sirt1 PDE4 AMPK 

Abbreviations

AMPK

Adenosine monophosphate activated kinase

Sirt1

Sirtuin 1

SIR2

Silent information regulator 2

cAMP

Cyclic adenosine monophosphate

CAMKKβ

Calcium/calmodulin-dependent kinase kinase β

PDE

Phosphodiesterases

PKA

Protein kinase A

EPAC

Exchange protein activated by cAMP

COX

Cyclooxygenase

HOMA-IR

Homeostatic model assessment-insulin resistance

eNOS

Endothelial nitric oxide synthase

Nrf2

Nuclear factor erythroid 2- related factor 2

Notes

Acknowledgments

This work was supported by the Intramural Research Program, National Heart Lung and Blood Institute, National Institutes of Health. We thank Alexandra Brown for manuscript preparation.

References

  1. 1.
    McCay CM, Crowell MF, Maynard LA (1935) The effect of retarded growth upon the length of life span and upon the ultimate body size. J Nutr 10:63–79Google Scholar
  2. 2.
    Heilbronn LK, Ravussin E (2003) Calorie restriction and aging: review of the literature and implications for studies in humans. Am J Clin Nutr 78:361–369PubMedGoogle Scholar
  3. 3.
    Lin SJ, Defossez PA, Guarente L (2000) Requirement of NAD and SIR2 for life-span extension by calorie restriction in Saccharomyces cerevisiae. Science 289:2126–2128PubMedGoogle Scholar
  4. 4.
    Howitz KT, Bitterman KJ, Cohen HY, Lamming DW, Lavu S, Wood JG, Zipkin RE, Chung P, Kisielewski A, Zhang LL, Scherer B, Sinclair DA (2003) Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 425:191–196PubMedGoogle Scholar
  5. 5.
    Jang MS, Cai EN, Udeani GO, Slowing KV, Thomas CF, Beecher CWW, Fong HHS, Farnsworth NR, Kinghorn AD, Mehta RG, Moon RC, Pezzuto JM (1997) Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 275:218–220PubMedGoogle Scholar
  6. 6.
    Park S-J, Ahmad F, Philp A, Baar K, Williams T, Luo H, Ke H, Rehmann H, Taussig R, Brown AL, Kim MK, Beaven MA, Burgin AB, Manganiello V, Chung JH (2012) Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases. Cell 148:421–433PubMedCentralPubMedGoogle Scholar
  7. 7.
    Gledhill JR, Montgomery MG, Leslie AGW, Walker JE (2007) Mechanism of inhibition of bovine F-1-ATPase by resveratrol and related polyphenols. Proc Natl Acad Sci USA 104:13632–13637PubMedCentralPubMedGoogle Scholar
  8. 8.
    Nwachukwu JC, Srinivasan S, Bruno NE, Parent AA, Hughes TS, Pollock JA, Gjyshi O, Cavett V, Nowak J, Garcia-Ordonez RD, Houtman R, Griffin PR, Kojetin DJ, Katzenellenbogen JA, Conkright MD, Nettles KW (2014) Resveratrol modulates the inflammatory response via an estrogen receptor-signal integration network. Elife (Cambridge) 3:e02057Google Scholar
  9. 9.
    Huberts DH, Gonzalez J, Lee SS, Litsios A, Hubmann G, Wit EC, Heinemann M (2014) Calorie restriction does not elicit a robust extension of replicative lifespan in Saccharomyces cerevisiae. Proc Natl Acad Sci USA 111:11727–11731PubMedCentralPubMedGoogle Scholar
  10. 10.
    Rogina B, Helfand SL (2004) Sir2 mediates longevity in the fly through a pathway related to calorie restriction. Proc Natl Acad Sci USA 101:15998–16003PubMedCentralPubMedGoogle Scholar
  11. 11.
    Wang YM, Tissenbaum HA (2006) Overlapping and distinct functions for a Caenorhabditis elegans SIR2 and DAF-16/FOXO. Mech Ageing Dev 127:48–56PubMedGoogle Scholar
  12. 12.
    Kaeberlein M, Kirkland KT, Fields S, Kennedy BK (2004) Sir2-independent life span extension by calorie restriction in yeast. PLoS Biol 2:1381–1387Google Scholar
  13. 13.
    Greer EL, Brunet A (2009) Different dietary restriction regimens extend lifespan by both independent and overlapping genetic pathways in C. elegans. Aging Cell 8:113–127PubMedCentralPubMedGoogle Scholar
  14. 14.
    Kaeberlein M, McVey M, Guarente L (1999) The SIR2/3/4 complex and SIR2 alone promote longevity in Saccharomyces cerevisiae by two different mechanisms. Genes Dev 13:2570–2580PubMedCentralPubMedGoogle Scholar
  15. 15.
    Tissenbaum HA, Guarente L (2001) Increased dosage of a sir-2 gene extends lifespan in Caenorhabditis elegans. Nature 410:227–230PubMedGoogle Scholar
  16. 16.
    Burnett C, Valentini S, Cabreiro F, Goss M, Somogyvari M, Piper MD, Hoddinott M, Sutphin GL, Leko V, McElwee JJ, Vazquez-Manrique RP, Orfila A-M, Ackerman D, Au C, Vinti G, Riesen M, Howard K, Neri C, Bedalov A, Kaeberlein M, Soti C, Partridge L, Gems D (2011) Absence of effects of Sir2 overexpression on lifespan in C. elegans and Drosophila. Nature 477:482 U136PubMedCentralPubMedGoogle Scholar
  17. 17.
    Viswanathan M, Guarente L (2011) Regulation of Caenorhabditis elegans lifespan by sir-2.1 transgenes. Nature 477:E1–E2PubMedGoogle Scholar
  18. 18.
    Banerjee KK, Ayyub C, Ali SZ, Mandot V, Prasad NG, Kolthur-Seetharam U (2012) dSir2 in the adult fat body, but not in muscles, regulates life span in a diet-dependent manner. Cell Rep 2:1485–1491PubMedGoogle Scholar
  19. 19.
    Bordone L, Cohen D, Robinson A, Motta MC, van Veen E, Czopik A, Steele AD, Crowe H, Marmor S, Luo J, Gu W, Guarente L (2007) SIRT1 transgenic mice show phenotypes resembling calorie restriction. Aging Cell 6:759–767PubMedGoogle Scholar
  20. 20.
    Banks AS, Kon N, Knight C, Matsumoto M, Gutierrez-Juarez R, Rossetti L, Gu W, Accili D (2008) SirT1 gain of function increases energy efficiency and prevents diabetes in mice. Cell Metab 8:333–341PubMedCentralPubMedGoogle Scholar
  21. 21.
    Satoh A, Brace CS, Rensing N, Cliften P, Wozniak DF, Herzog ED, Yamada KA, Imai S (2013) Sirt1 extends life span and delays aging in mice through the regulation of Nk2 homeobox 1 in the DMH and LH. Cell Metab 18:416–430PubMedCentralPubMedGoogle Scholar
  22. 22.
    Qiang L, Lin HV, Kim-Muller JY, Welch CL, Gu W, Accili D (2011) Proatherogenic abnormalities of lipid metabolism in SirT1 transgenic mice are mediated through Creb deacetylation. Cell Metab 14:758–767PubMedCentralPubMedGoogle Scholar
  23. 23.
    Kawashima T, Inuzuka Y, Okuda J, Kato T, Niizuma S, Tamaki Y, Iwanaga Y, Kawamoto A, Narazaki M, Matsuda T, Adachi S, Takemura G, Kita T, Kimura T, Shioi T (2011) Constitutive SIRT1 overexpression impairs mitochondria and reduces cardiac function in mice. J Mol Cell Cardiol 51:1026–1036PubMedGoogle Scholar
  24. 24.
    Bitterman KJ, Anderson RM, Cohen HY, Latorre-Esteves M, Sinclair DA (2002) Inhibition of silencing and accelerated aging by nicotinamide, a putative negative regulator of yeast sir2 and human SIRT1. J Biol Chem 277:45099–45107PubMedGoogle Scholar
  25. 25.
    Borra MT, Smith BC, Denu JM (2005) Mechanism of human SIRT1 activation by resveratrol. J Biol Chem 280:17187–17195PubMedGoogle Scholar
  26. 26.
    Kaeberlein M, McDonagh T, Heltweg B, Hixon J, Westman EA, Caldwell SD, Napper A, Curtis R, DiStefano PS, Fields S, Bedalov A, Kennedy BK (2005) Substrate-specific activation of sirtuins by resveratrol. J Biol Chem 280:17038–17045PubMedGoogle Scholar
  27. 27.
    Pacholec M, Bleasdale JE, Chrunyk B, Cunningham D, Flynn D, Garofalo RS, Griffith D, Griffor M, Loulakis P, Pabst B, Qiu X, Stockman B, Thanabal V, Varghese A, Ward J, Withka J, Ahn K (2010) SRT1720, SRT2183, SRT1460, and resveratrol are not direct activators of SIRT1. J Biol Chem 285:8340–8351PubMedCentralPubMedGoogle Scholar
  28. 28.
    Huber JL, McBurney MW, DiStefano PS, McDonagh T (2010) SIRT1-independent mechanisms of the putative sirtuin enzyme activators SRT1720 and SRT2183. Future Med Chem 2:1751–1759PubMedGoogle Scholar
  29. 29.
    Dai H, Kustigian L, Carney D, Case A, Considine T, Hubbard BP, Perni RB, Riera TV, Szczepankiewicz B, Vlasuk GP, Stein RL (2010) SIRT1 Activation by small molecules kinetic and biophysical evidence for direct interaction of enzyme and activator. J Biol Chem 285:32695–32703PubMedCentralPubMedGoogle Scholar
  30. 30.
    Gertz M, Nguyen GT, Fischer F, Suenkel B, Schlicker C, Franzel B, Tomaschewski J, Aladini F, Becker C, Wolters D, Steegborn C (2012) A molecular mechanism for direct sirtuin activation by resveratrol. PLoS One 7:e49761PubMedCentralPubMedGoogle Scholar
  31. 31.
    Lakshminarasimhan M, Rauh D, Schutkowski M, Steegborn C (2013) Sirt1 activation by resveratrol is substrate sequence-selective. Aging (Albany NY) 5:151–154Google Scholar
  32. 32.
    Hubbard BP, Gomes AP, Dai H, Li J, Case AW, Considine T, Riera TV, Lee JE, E SY, Lamming DW, Pentelute BL, Schuman ER, Stevens LA, Ling AJ, Armour SM, Michan S, Zhao H, Jiang Y, Sweitzer SM, Blum CA, Disch JS, Ng PY, Howitz KT, Rolo AP, Hamuro Y, Moss J, Perni RB, Ellis JL, Vlasuk GP, Sinclair DA (2013) Evidence for a common mechanism of SIRT1 regulation by allosteric activators. Science 339:1216–1219PubMedCentralPubMedGoogle Scholar
  33. 33.
    Dasgupta B, Milbrandt J (2007) Resveratrol stimulates AMP kinase activity in neurons. Proc Natl Acad Sci USA 104:7217–7222PubMedCentralPubMedGoogle Scholar
  34. 34.
    Zang M, Xu S, Maitland-Toolan KA, Zuccollo A, Hou X, Jiang B, Wierzbicki M, Verbeuren TJ, Cohen RA (2006) Polyphenols stimulate AMP-activated protein kinase, lower lipids, and inhibit accelerated atherosclerosis in diabetic LDL receptor-deficient mice. Diabetes 55:2180–2191PubMedGoogle Scholar
  35. 35.
    Baur JA, Pearson KJ, Price NL, Jamieson HA, Lerin C, Kalra A, Prabhu VV, Allard JS, Lopez-Lluch G, Lewis K, Pistell PJ, Poosala S, Becker KG, Boss O, Gwinn D, Wang M, Ramaswamy S, Fishbein KW, Spencer RG, Lakatta EG, Le Couteur D, Shaw RJ, Navas P, Puigserver P, Ingram DK, de Cabo R, Sinclair DA (2006) Resveratrol improves health and survival of mice on a high-calorie diet. Nature 444:337–342PubMedGoogle Scholar
  36. 36.
    Canto C, Jiang LQ, Deshmukh AS, Mataki C, Coste A, Lagouge M, Zierath JR, Auwerx J (2010) Interdependence of AMPK and SIRT1 for metabolic adaptation to fasting and exercise in skeletal muscle. Cell Metab 11:213–219PubMedCentralPubMedGoogle Scholar
  37. 37.
    Hwang JT, Kwak DW, Lin SK, Kim HM, Kim YM, Park OJ (2007) Resveratrol induces apoptosis in chemoresistant cancer cells via modulation of AMPK signaling pathway. Ann N Y Acad Sci 1095:441–448PubMedGoogle Scholar
  38. 38.
    Park CE, Kim MJ, Lee JH, Min BI, Bae H, Choe W, Kim SS, Ha J (2007) Resveratrol stimulates glucose transport in C2C12 myotubes by activating AMP-activated protein kinase. Exp Mol Med 39:222–229PubMedGoogle Scholar
  39. 39.
    Um JH, Park SJ, Kang H, Yang S, Foretz M, McBurney MW, Kim MK, Viollet B, Chung JH (2010) AMP-activated protein kinase-deficient mice are resistant to the metabolic effects of resveratrol. Diabetes 59:554–563PubMedCentralPubMedGoogle Scholar
  40. 40.
    Hardie DG, Ross FA, Hawley SA (2012) AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nat Rev Mol Cell Biol 13:251–262PubMedGoogle Scholar
  41. 41.
    Palacios OM, Carmona JJ, Michan S, Chen KY, Manabe Y, Ward JL III, Goodyear LJ, Tong Q (2009) Diet and exercise signals regulate SIRT3 and activate AMPK and PGC-1 alpha in skeletal muscle. Aging-Us 1:771–783Google Scholar
  42. 42.
    Edwards AG, Donato AJ, Lesniewski LA, Gioscia RA, Seals DR, Moore RL (2010) Life-long caloric restriction elicits pronounced protection of the aged myocardium: a role for AMPK. Mech Ageing Dev 131:739–742PubMedCentralPubMedGoogle Scholar
  43. 43.
    Canto C, Jiang LQ, Deshmukh AS, Mataki C, Coste A, Lagouge M, Zierath JR, Auwerx J (2010) Interdependence of AMPK and SIRT1 for metabolic adaptation to fasting and exercise in skeletal muscle. Cell Metab 11:213–219PubMedCentralPubMedGoogle Scholar
  44. 44.
    Hawley SA, Ross FA, Chevtzoff C, Green KA, Evans A, Fogarty S, Towler MC, Brown LJ, Ogunbayo OA, Evans AM, Hardie DG (2010) Use of cells expressing gamma subunit variants to identify diverse mechanisms of AMPK activation. Cell Metab 11:554–565PubMedCentralPubMedGoogle Scholar
  45. 45.
    Zheng J, Ramirez VD (2000) Inhibition of mitochondrial proton F0F1-ATPase/ATP synthase by polyphenolic phytochemicals. Br J Pharmacol 130:1115–1123PubMedCentralPubMedGoogle Scholar
  46. 46.
    Price NL, Gomes AP, Ling AJY, Duarte FV, Martin-Montalvo A, North BJ, Agarwal B, Ye L, Ramadori G, Teodoro JS, Hubbard BP, Varela AT, Davis JG, Varamini B, Hafner A, Moaddel R, Rolo AP, Coppari R, Palmeira CM, de Cabo R, Baur JA, Sinclair DA (2012) SIRT1 is required for AMPK activation and the beneficial effects of resveratrol on mitochondrial function. Cell Metab 15:675–690PubMedCentralPubMedGoogle Scholar
  47. 47.
    Suchankova G, Nelson LE, Gerhart-Hines Z, Kelly M, Gauthier MS, Saha AK, Ido Y, Puigserver P, Ruderman NB (2009) Concurrent regulation of AMP-activated protein kinase and SIRT1 in mammalian cells. Biochem Biophys Res Commun 378:836–841PubMedCentralPubMedGoogle Scholar
  48. 48.
    Feige JN, Lagouge M, Canto C, Strehle A, Houten SM, Milne JC, Lambert PD, Mataki C, Elliott PJ, Auwerx J (2008) Specific SIRT1 activation mimics low energy levels and protects against diet-induced metabolic disorders by enhancing fat oxidation. Cell Metab 8:347–358PubMedGoogle Scholar
  49. 49.
    Price NL, Gomes AP, Ling AJ, Duarte FV, Martin-Montalvo A, North BJ, Agarwal B, Ye L, Ramadori G, Teodoro JS, Hubbard BP, Varela AT, Davis JG, Varamini B, Hafner A, Moaddel R, Rolo AP, Coppari R, Palmeira CM, de Cabo R, Baur JA, Sinclair DA (2012) SIRT1 is required for AMPK activation and the beneficial effects of resveratrol on mitochondrial function. Cell Metab 15:675–690PubMedCentralPubMedGoogle Scholar
  50. 50.
    Conti M, Beavo J (2007) Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling. Annu Rev Biochem 76:481–511PubMedGoogle Scholar
  51. 51.
    Vingtdeux V, Giliberto L, Zhao H, Chandakkar P, Wu Q, Simon JE, Janle EM, Lobo J, Ferruzzi MG, Davies P, Marambaud P (2010) AMP-activated protein kinase signaling activation by resveratrol modulates amyloid-beta peptide metabolism. J Biol Chem 285:9100–9113PubMedCentralPubMedGoogle Scholar
  52. 52.
    Chung JH, Manganiello V, Dyck JR (2012) Resveratrol as a calorie restriction mimetic: therapeutic implications. Trends Cell Biol 22:546–554PubMedCentralPubMedGoogle Scholar
  53. 53.
    Shelly M, Cancedda L, Heilshorn S, Sumbre G, Poo MM (2007) LKB1/STRAD promotes axon initiation during neuronal polarization. Cell 129:565–577PubMedGoogle Scholar
  54. 54.
    Fogarty S, Hardie DG (2009) C-terminal phosphorylation of LKB1 is not required for regulation of AMP-activated protein kinase, BRSK1, BRSK2, or cell cycle arrest. J Biol Chem 284:77–84PubMedCentralPubMedGoogle Scholar
  55. 55.
    Djouder N, Tuerk RD, Suter M, Salvioni P, Thali RF, Scholz R, Vaahtomeri K, Auchli Y, Rechsteiner H, Brunisholz RA, Viollet B, Makela TP, Wallimann T, Neumann D, Krek W (2010) PKA phosphorylates and inactivates AMPKalpha to promote efficient lipolysis. EMBO J 29:469–481PubMedCentralPubMedGoogle Scholar
  56. 56.
    Medina EA, Oberheu K, Polusani SR, Ortega V, Velagaleti GV, Oyajobi BO (2014) PKA/AMPK signaling in relation to adiponectin’s antiproliferative effect on multiple myeloma cells. LeukemiaGoogle Scholar
  57. 57.
    Omar B, Zmuda-Trzebiatowska E, Manganiello V, Goransson O, Degerman E (2009) Regulation of AMP-activated protein kinase by cAMP in adipocytes: roles for phosphodiesterases, protein kinase B, protein kinase A, Epac and lipolysis. Cell Signal 21:760–766PubMedCentralPubMedGoogle Scholar
  58. 58.
    Pulinilkunnil T, He H, Kong D, Asakura K, Peroni OD, Lee A, Kahn BB (2011) Adrenergic regulation of AMP-activated protein kinase in brown adipose tissue in vivo. J Biol Chem 286:8798–8809PubMedCentralPubMedGoogle Scholar
  59. 59.
    Kelly M, Gauthier MS, Saha AK, Ruderman NB (2009) Activation of AMP-activated protein kinase by interleukin-6 in rat skeletal muscle: association with changes in cAMP, energy state, and endogenous fuel mobilization. Diabetes 58:1953–1960PubMedCentralPubMedGoogle Scholar
  60. 60.
    Gerhart-Hines Z, Dominy JE Jr, Blattler SM, Jedrychowski MP, Banks AS, Lim JH, Chim H, Gygi SP, Puigserver P (2011) The cAMP/PKA pathway rapidly activates SIRT1 to promote fatty acid oxidation independently of changes in NAD(+). Mol Cell 44:851–863PubMedCentralPubMedGoogle Scholar
  61. 61.
    Nin V, Escande C, Chini CC, Giri S, Camacho-Pereira J, Matalonga J, Lou Z, Chini EN (2012) Role of deleted in breast cancer 1 (DBC1) protein in SIRT1 deacetylase activation induced by protein kinase A and AMP-activated protein kinase. J Biol Chem 287:23489–23501PubMedCentralPubMedGoogle Scholar
  62. 62.
    Kashyap SS, Johnson JR, McCue HV, Chen X, Edmonds MJ, Ayala M, Graham ME, Jenn RC, Barclay JW, Burgoyne RD, Morgan A (2014) Caenorhabditis elegans dnj-14, the orthologue of the DNAJC5 gene mutated in adult onset neuronal ceroid lipofuscinosis, provides a new platform for neuroprotective drug screening and identifies a SIR-2.1-independent action of resveratrol. Hum Mol GenetGoogle Scholar
  63. 63.
    Lissa D, Senovilla L, Rello-Varona S, Vitale I, Michaud M, Pietrocola F, Boileve A, Obrist F, Bordenave C, Garcia P, Michels J, Jemaa M, Kepp O, Castedo M, Kroemer G (2014) Resveratrol and aspirin eliminate tetraploid cells for anticancer chemoprevention. Proc Natl Acad Sci USA 111:3020–3025PubMedCentralPubMedGoogle Scholar
  64. 64.
    Tikoo K, Lodea S, Karpe PA, Kumar S (2014) Calorie restriction mimicking effects of roflumilast prevents diabetic nephropathy. Biochem Biophys Res CommunGoogle Scholar
  65. 65.
    Szewczuk LM, Forti L, Stivala LA, Penning TM (2004) Resveratrol is a peroxidase-mediated inactivator of COX-1 but not COX-2: a mechanistic approach to the design of COX-1 selective agents. J Biol Chem 279:22727–22737PubMedGoogle Scholar
  66. 66.
    Agarwal B, Baur JA (2011) Resveratrol and life extension. Ann N Y Acad Sci 1215:138–143PubMedGoogle Scholar
  67. 67.
    Zini R, Morin C, Bertelli A, Bertelli AA, Tillement JP (1999) Effects of resveratrol on the rat brain respiratory chain. Drugs Exp Clin Res 25:87–97PubMedGoogle Scholar
  68. 68.
    Moreira AC, Silva AM, Santos MS, Sardao VA (2013) Resveratrol affects differently rat liver and brain mitochondrial bioenergetics and oxidative stress in vitro: investigation of the role of gender. Food Chem Toxicol 53:18–26PubMedGoogle Scholar
  69. 69.
    Desquiret-Dumas V, Gueguen N, Leman G, Baron S, Nivet-Antoine V, Chupin S, Chevrollier A, Vessieres E, Ayer A, Ferre M, Bonneau D, Henrion D, Reynier P, Procaccio V (2013) Resveratrol induces a mitochondrial complex I-dependent increase in NADH oxidation responsible for sirtuin activation in liver cells. J Biol Chem 288:36662–36675PubMedCentralPubMedGoogle Scholar
  70. 70.
    Gehm BD, McAndrews JM, Chien PY, Jameson JL (1997) Resveratrol, a polyphenolic compound found in grapes and wine, is an agonist for the estrogen receptor. Proc Natl Acad Sci USA 94:14138–14143PubMedCentralPubMedGoogle Scholar
  71. 71.
    Bowers JL, Tyulmenkov VV, Jernigan SC, Klinge CM (2000) Resveratrol acts as a mixed agonist/antagonist for estrogen receptors alpha and beta. Endocrinology 141:3657–3667PubMedGoogle Scholar
  72. 72.
    Turner RT, Evans GL, Zhang M, Maran A, Sibonga JD (1999) Is resveratrol an estrogen agonist in growing rats? Endocrinology 140:50–54PubMedGoogle Scholar
  73. 73.
    Lee JH, Guo Z, Myler LR, Zheng S, Paull TT (2014) Direct activation of ATM by resveratrol under oxidizing conditions. PLoS One 9:e97969PubMedCentralPubMedGoogle Scholar
  74. 74.
    Hussain AR, Uddin S, Bu R, Khan OS, Ahmed SO, Ahmed M, Al-Kuraya KS (2011) Resveratrol suppresses constitutive activation of AKT via generation of ROS and induces apoptosis in diffuse large B cell lymphoma cell lines. PLoS One 6:e24703PubMedCentralPubMedGoogle Scholar
  75. 75.
    Guo Z, Kozlov S, Lavin MF, Person MD, Paull TT (2010) ATM activation by oxidative stress. Science 330:517–521PubMedGoogle Scholar
  76. 76.
    Wood JG, Rogina B, Lavu S, Howitz K, Helfand SL, Tatar M, Sinclair D (2004) Sirtuin activators mimic caloric restriction and delay ageing in metazoans. Nature 430:686–689PubMedGoogle Scholar
  77. 77.
    Valenzano DR, Terzibasi E, Genade T, Cattaneo A, Domenici L, Cellerino A (2006) Resveratrol prolongs lifespan and retards the onset of age-related markers in a short-lived vertebrate. Curr Biol 16:296–300PubMedGoogle Scholar
  78. 78.
    Yu X, Li G (2012) Effects of resveratrol on longevity, cognitive ability and aging-related histological markers in the annual fish Nothobranchius guentheri. Exp Gerontol 47:940–949PubMedGoogle Scholar
  79. 79.
    Rascon B, Hubbard BP, Sinclair DA, Amdam GV (2012) The lifespan extension effects of resveratrol are conserved in the honey bee and may be driven by a mechanism related to caloric restriction. Aging (Albany NY) 4:499–508Google Scholar
  80. 80.
    Pearson KJ, Baur JA, Lewis KN, Peshkin L, Price NL, Labinskyy N, Swindell WR, Kamara D, Minor RK, Perez E, Jamieson HA, Zhang Y, Dunn SR, Sharma K, Pleshko N, Woollett LA, Csiszar A, Ikeno Y, Le Couteur D, Elliott PJ, Becker KG, Navas P, Ingram DK, Wolf NS, Ungvari Z, Sinclair DA, de Cabo R (2008) Resveratrol delays age-related deterioration and mimics transcriptional aspects of dietary restriction without extending life span. Cell Metab 8:157–168PubMedCentralPubMedGoogle Scholar
  81. 81.
    Miller RA, Harrison DE, Astle CM, Baur JA, Boyd AR, de Cabo R, Fernandez E, Flurkey K, Javors MA, Nelson JF, Orihuela CJ, Pletcher S, Sharp ZD, Sinclair D, Starnes JW, Wilkinson JE, Nadon NL, Strong R (2011) Rapamycin, but not resveratrol or simvastatin, extends life span of genetically heterogeneous mice. J Gerontol A Biol Sci Med Sci 66:191–201PubMedGoogle Scholar
  82. 82.
    Strong R, Miller RA, Astle CM, Baur JA, de Cabo R, Fernandez E, Guo W, Javors M, Kirkland JL, Nelson JF, Sinclair DA, Teter B, Williams D, Zaveri N, Nadon NL, Harrison DE (2013) Evaluation of resveratrol, green tea extract, curcumin, oxaloacetic acid, and medium-chain triglyceride oil on life span of genetically heterogeneous mice. J Gerontol A Biol Sci Med Sci 68:6–16PubMedCentralPubMedGoogle Scholar
  83. 83.
    da Luz PL, Tanaka L, Brum PC, Dourado PM, Favarato D, Krieger JE, Laurindo FR (2012) Red wine and equivalent oral pharmacological doses of resveratrol delay vascular aging but do not extend life span in rats. Atherosclerosis 224:136–142PubMedGoogle Scholar
  84. 84.
    Mattison JA, Roth GS, Beasley TM, Tilmont EM, Handy AM, Herbert RL, Longo DL, Allison DB, Young JE, Bryant M, Barnard D, Ward WF, Qi W, Ingram DK, de Cabo R (2012) Impact of caloric restriction on health and survival in rhesus monkeys from the NIA study. Nature 489:318–321PubMedGoogle Scholar
  85. 85.
    Colman RJ, Anderson RM, Johnson SC, Kastman EK, Kosmatka KJ, Beasley TM, Allison DB, Cruzen C, Simmons HA, Kemnitz JW, Weindruch R (2009) Caloric restriction delays disease onset and mortality in rhesus monkeys. Science 325:201–204PubMedCentralPubMedGoogle Scholar
  86. 86.
    Wang C, Wheeler CT, Alberico T, Sun X, Seeberger J, Laslo M, Spangler E, Kern B, de Cabo R, Zou S (2013) The effect of resveratrol on lifespan depends on both gender and dietary nutrient composition in Drosophila melanogaster. Age (Dordr) 35:69–81Google Scholar
  87. 87.
    Lagouge M, Argmann C, Gerhart-Hines Z, Meziane H, Lerin C, Daussin F, Messadeq N, Milne J, Lambert P, Elliott P, Geny B, Laakso M, Puigserver P, Auwerx J (2006) Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1 alpha. Cell 127:1109–1122PubMedGoogle Scholar
  88. 88.
    Pfluger PT, Herranz D, Velasco-Miguel S, Serrano M, Tschop MH (2008) Sirt1 protects against high-fat diet-induced metabolic damage. Proc Natl Acad Sci USA 105:9793–9798PubMedCentralPubMedGoogle Scholar
  89. 89.
    Banks AS, Kon N, Knight C, Matsumoto M, Gutierrez-Juarez R, Rossetti L, Gu W, Accili D (2008) SirT1 gain of function increases energy efficiency and prevents diabetes in mice. Cell Metab 8:333–341PubMedCentralPubMedGoogle Scholar
  90. 90.
    Puigserver P, Wu Z, Park CW, Graves R, Wright M, Spiegelman BM (1998) A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis. Cell 92:829–839PubMedGoogle Scholar
  91. 91.
    Lin J, Wu H, Tarr PT, Zhang CY, Wu Z, Boss O, Michael LF, Puigserver P, Isotani E, Olson EN, Lowell BB, Bassel-Duby R, Spiegelman BM (2002) Transcriptional co-activator PGC-1 alpha drives the formation of slow-twitch muscle fibres. Nature 418:797–801PubMedGoogle Scholar
  92. 92.
    Wenz T, Rossi SG, Rotundo RL, Spiegelman BM, Moraes CT (2009) Increased muscle PGC-1 alpha expression protects from sarcopenia and metabolic disease during aging. Proc Natl Acad Sci USA 106:20405–20410PubMedCentralPubMedGoogle Scholar
  93. 93.
    Rodgers JT, Lerin C, Haas W, Gygi SP, Spiegelman BM, Puigserver P (2005) Nutrient control of glucose homeostasis through a complex of PGC-1 alpha and SIRT1. Nature 434:113–118PubMedGoogle Scholar
  94. 94.
    Canto C, Gerhart-Hines Z, Feige JN, Lagouge M, Noriega L, Milne JC, Elliott PJ, Puigserver P, Auwerx J (2009) AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity. Nature 458:1056–1060PubMedCentralPubMedGoogle Scholar
  95. 95.
    Nemoto S, Fergusson MM, Finkel T (2005) SIRT1 functionally interacts with the metabolic regulator and transcriptional coactivator PGC-1{alpha}. J Biol Chem 280:16456–16460PubMedGoogle Scholar
  96. 96.
    Higashida K, Kim SH, Jung SR, Asaka M, Holloszy JO, Han DH (2013) Effects of resveratrol and SIRT1 on PGC-1alpha activity and mitochondrial biogenesis: a reevaluation. PLoS Biol 11:e1001603PubMedCentralPubMedGoogle Scholar
  97. 97.
    Fulco M, Cen Y, Zhao P, Hoffman EP, McBurney MW, Sauve AA, Sartorelli V (2008) Glucose restriction inhibits skeletal myoblast differentiation by activating SIRT1 through AMPK-mediated regulation of Nampt. Dev Cell 14:661–673PubMedCentralPubMedGoogle Scholar
  98. 98.
    Hou X, Xu S, Maitland-Toolan KA, Sato K, Jiang B, Ido Y, Lan F, Walsh K, Wierzbicki M, Verbeuren TJ, Cohen RA, Zang M (2008) SIRT1 regulates hepatocyte lipid metabolism through activating AMP-activated protein kinase. J Biol Chem 283:20015–20026PubMedCentralPubMedGoogle Scholar
  99. 99.
    Lan F, Cacicedo JM, Ruderman N, Ido Y (2008) SIRT1 modulation of the acetylation status, cytosolic localization, and activity of LKB1—possible role in AMP-activated protein kinase activation. J Biol Chem 283:27628–27635PubMedCentralPubMedGoogle Scholar
  100. 100.
    Bai P, Canto C, Oudart H, Brunyanszki A, Cen Y, Thomas C, Yamamoto H, Huber A, Kiss B, Houtkooper RH, Schoonjans K, Schreiber V, Sauve AA, Menissier-de Murcia J, Auwerx J (2011) PARP-1 inhibition increases mitochondrial metabolism through SIRT1 activation. Cell Metab 13:461–468PubMedCentralPubMedGoogle Scholar
  101. 101.
    Walz HA, Wierup N, Vikman J, Manganiello VC, Degerman E, Eliasson L, Holst LS (2007) Beta-cell PDE3B regulates Ca2+ -stimulated exocytosis of insulin. Cell Signal 19:1505–1513PubMedGoogle Scholar
  102. 102.
    Choi YH, Park S, Hockman S, Zmuda-Trzebiatowska E, Svennelid F, Haluzik M, Gavrilova O, Ahmad F, Pepin L, Napolitano M, Taira M, Sundler F, Stenson Holst L, Degerman E, Manganiello VC (2006) Alterations in regulation of energy homeostasis in cyclic nucleotide phosphodiesterase 3B-null mice. J Clin Invest 116:3240–3251PubMedCentralPubMedGoogle Scholar
  103. 103.
    Zhang R, Maratos-Flier E, Flier JS (2009) Reduced adiposity and high-fat diet-induced adipose inflammation in mice deficient for phosphodiesterase 4B. Endocrinology 150:3076–3082PubMedCentralPubMedGoogle Scholar
  104. 104.
    McBurney MW, Yang XF, Jardine K, Hixon M, Boekelheide K, Webb JR, Lansdorp PM, Lemieux M (2003) The mammalian SIR2 alpha protein has a role in embryogenesis and gametogenesis. Mol Cell Biol 23:38–54PubMedCentralPubMedGoogle Scholar
  105. 105.
    Cheng HL, Mostoslavsky R, Saito S, Manis JP, Gu YS, Patel P, Bronson R, Appella E, Alt FW, Chua KF (2003) Developmental defects and p53 hyperacetylation in Sir2 homolog (SIRT1)-deficient mice. Proc Natl Acad Sci USA 100:10794–10799PubMedCentralPubMedGoogle Scholar
  106. 106.
    Kang W, Hong HJ, Guan J, Kim DG, Yang EJ, Koh G, Park D, Han CH, Lee YJ, Lee DH (2012) Resveratrol improves insulin signaling in a tissue-specific manner under insulin-resistant conditions only: in vitro and in vivo experiments in rodents. Metabolism 61:424–433PubMedGoogle Scholar
  107. 107.
    Poulsen MM, Larsen JO, Hamilton-Dutoit S, Clasen BF, Jessen N, Paulsen SK, Kjaer TN, Richelsen B, Pedersen SB (2012) Resveratrol up-regulates hepatic uncoupling protein 2 and prevents development of nonalcoholic fatty liver disease in rats fed a high-fat diet. Nutr Res 32:701–708PubMedGoogle Scholar
  108. 108.
    Milne JC, Lambert PD, Schenk S, Carney DP, Smith JJ, Gagne DJ, Jin L, Boss O, Perni RB, Vu CB, Bemis JE, Xie R, Disch JS, Ng PY, Nunes JJ, Lynch AV, Yang H, Galonek H, Israelian K, Choy W, Iffland A, Lavu S, Medvedik O, Sinclair DA, Olefsky JM, Jirousek MR, Elliott PJ, Westphal CH (2007) Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature 450:712–716PubMedCentralPubMedGoogle Scholar
  109. 109.
    Minor RK, Baur JA, Gomes AP, Ward TM, Csiszar A, Mercken EM, Abdelmohsen K, Shin Y-K, Canto C, Scheibye-Knudsen M, Krawczyk M, Irusta PM, Martin-Montalvo A, Hubbard BP, Zhang Y, Lehrmann E, White AA, Price NL, Swindell WR, Pearson KJ, Becker KG, Bohr VA, Gorospe M, Egan JM, Talan MI, Auwerx J, Westphal CH, Ellis JL, Ungvari Z, Vlasuk GP, Elliott PJ, Sinclair DA, de Cabo R (2011) SRT1720 improves survival and healthspan of obese mice. Sci Rep 1:70PubMedCentralPubMedGoogle Scholar
  110. 110.
    Beaudoin MS, Snook LA, Arkell AM, Simpson JA, Holloway GP, Wright DC (2013) Resveratrol supplementation improves white adipose tissue function in a depot-specific manner in Zucker diabetic fatty rats. Am J Physiol Regul Integr Comp Physiol 305:R542–R551PubMedGoogle Scholar
  111. 111.
    Fiori JL, Shin YK, Kim W, Krzysik-Walker SM, Gonzalez-Mariscal I, Carlson OD, Sanghvi M, Moaddel R, Farhang K, Gadkaree SK, Doyle ME, Pearson KJ, Mattison JA, de Cabo R, Egan JM (2013) Resveratrol prevents beta-cell dedifferentiation in nonhuman primates given a high-fat/high-sugar diet. Diabetes 62:3500–3513PubMedCentralPubMedGoogle Scholar
  112. 112.
    Jimenez-Gomez Y, Mattison JA, Pearson KJ, Martin-Montalvo A, Palacios HH, Sossong AM, Ward TM, Younts CM, Lewis K, Allard JS, Longo DL, Belman JP, Malagon MM, Navas P, Sanghvi M, Moaddel R, Tilmont EM, Herbert RL, Morrell CH, Egan JM, Baur JA, Ferrucci L, Bogan JS, Bernier M, de Cabo R (2013) Resveratrol improves adipose insulin signaling and reduces the inflammatory response in adipose tissue of rhesus monkeys on high-fat, high-sugar diet. Cell Metab 18:533–545PubMedGoogle Scholar
  113. 113.
    Marchal J, Blanc S, Epelbaum J, Aujard F, Pifferi F (2012) Effects of chronic calorie restriction or dietary resveratrol supplementation on insulin sensitivity markers in a primate. Microcebus murinus. PLoS One 7:e34289Google Scholar
  114. 114.
    Chung HY, Cesari M, Anton S, Marzetti E, Giovannini S, Seo AY, Carter C, Yu BP, Leeuwenburgh C (2009) Molecular inflammation: underpinnings of aging and age-related diseases. Ageing Res Rev 8:18–30PubMedCentralPubMedGoogle Scholar
  115. 115.
    Donath MY, Shoelson SE (2011) Type 2 diabetes as an inflammatory disease. Nat Rev Immunol 11:98–107PubMedGoogle Scholar
  116. 116.
    Kimura Y, Okuda H, Arichi S (1985) Effects of stilbenes on arachidonate metabolism in leukocytes. Biochim Biophys Acta 834:275–278PubMedGoogle Scholar
  117. 117.
    Harikumar KB, Aggarwal BB (2008) Resveratrol: a multitargeted agent for age-associated chronic diseases. Cell Cycle 7:1020–1035PubMedGoogle Scholar
  118. 118.
    Wirleitner B, Schroecksnadel K, Winkler C, Schennach HS, Fuchs D (2005) Resveratrol suppresses interferon-gamma-induced biochemical pathways in human peripheral blood mononuclear cells in vitro. Immunol Lett 100:159–163PubMedGoogle Scholar
  119. 119.
    Rachon D, Rimoldi G, Wuttke W (2006) In vitro effects of genistein and resveratrol on the production of interferon-gamma (IFNgamma) and interleukin-10 (IL-10) by stimulated murine splenocytes. Phytomedicine 13:419–424PubMedGoogle Scholar
  120. 120.
    Lanzilli G, Cottarelli A, Nicotera G, Guida S, Ravagnan G, Fuggetta MP (2012) Anti-inflammatory effect of resveratrol and polydatin by in vitro IL-17 modulation. Inflammation 35:240–248PubMedGoogle Scholar
  121. 121.
    Yeung F, Hoberg JE, Ramsey CS, Keller MD, Jones DR, Frye RA, Mayo MW (2004) Modulation of NF-kappa B-dependent transcription and cell survival by the SIRT1 deacetylase. EMBO J 23:2369–2380PubMedCentralPubMedGoogle Scholar
  122. 122.
    Tao HY, Wu CF, Zhou Y, Gong WH, Zhang X, Iribarren P, Zhao YQ, Le YY, Wang JM (2004) The grape component resveratrol interferes with the function of chemoattractant receptors on phagocytic leukocytes. Cell Mol Immunol 1:50–56PubMedGoogle Scholar
  123. 123.
    Baur JA, Ungvari Z, Minor RK, Le Couteur DG, de Cabo R (2012) Are sirtuins viable targets for improving healthspan and lifespan? Nat Rev Drug Discov 11:443–461PubMedGoogle Scholar
  124. 124.
    Dioum EM, Chen R, Alexander MS, Zhang Q, Hogg RT, Gerard RD, Garcia JA (2009) Regulation of hypoxia-inducible factor 2 alpha signaling by the stress-responsive deacetylase sirtuin 1. Science 324:1289–1293PubMedGoogle Scholar
  125. 125.
    Brunet A, Sweeney LB, Sturgill JF, Chua KF, Greer PL, Lin YX, Tran H, Ross SE, Mostoslavsky R, Cohen HY, Hu LS, Cheng HL, Jedrychowski MP, Gygi SP, Sinclair DA, Alt FW, Greenberg ME (2004) Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science 303:2011–2015PubMedGoogle Scholar
  126. 126.
    van der Horst A, Tertoolen LGJ, de Vries-Smits LMM, Frye RA, Medema RH, Burgering BMT (2004) FOXO4 is acetylated upon peroxide stress and deacetylated by the longevity protein hSir2(SIRT1). J Biol Chem 279:28873–28879PubMedGoogle Scholar
  127. 127.
    Motta MC, Divecha N, Lemieux M, Kamel C, Chen D, Gu W, Bultsma Y, McBurney M, Guarente L (2004) Mammalian SIRT1 represses forkhead transcription factors. Cell 116:551–563PubMedGoogle Scholar
  128. 128.
    Rahal K, Schmiedlin-Ren P, Adler J, Dhanani M, Sultani V, Rittershaus AC, Reingold L, Zhu J, McKenna BJ, Christman GM, Zimmermann EM (2012) Resveratrol has antiinflammatory and antifibrotic effects in the peptidoglycan-polysaccharide rat model of Crohn’s disease. Inflamm Bowel Dis 18:613–623PubMedCentralPubMedGoogle Scholar
  129. 129.
    Baur JA, Sinclair DA (2006) Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov 5:493–506PubMedGoogle Scholar
  130. 130.
    Dolinsky VW, Dyck JR (2011) Calorie restriction and resveratrol in cardiovascular health and disease. Biochim Biophys Acta 1812:1477–1489PubMedGoogle Scholar
  131. 131.
    Tome-Carneiro J, Gonzalvez M, Larrosa M, Yanez-Gascon MJ, Garcia-Almagro FJ, Ruiz-Ros JA, Tomas-Barberan FA, Garcia-Conesa MT, Espin JC (2013) Resveratrol in primary and secondary prevention of cardiovascular disease: a dietary and clinical perspective. Ann N Y Acad Sci 1290:37–51PubMedGoogle Scholar
  132. 132.
    Wallerath T, Deckert G, Ternes T, Anderson H, Li H, Witte K, Forstermann U (2002) Resveratrol, a polyphenolic phytoalexin present in red wine, enhances expression and activity of endothelial nitric oxide synthase. Circulation 106:1652–1658PubMedGoogle Scholar
  133. 133.
    Taubert D, Berkels R (2003) Upregulation and activation of eNOS by resveratrol. Circulation 107:E78–E79PubMedGoogle Scholar
  134. 134.
    Pearson KJ, Baur JA, Lewis KN, Peshkin L, Price NL, Labinskyy N, Swindell WR, Kamara D, Minor RK, Perez E, Jamieson HA, Zhang Y, Dunn SR, Sharma K, Pleshko N, Woollett LA, Csiszar A, Ikeno Y, Le Couteur D, Elliott PJ, Becker KG, Navas P, Ingram DK, Wolf NS, Ungvari Z, Sinclair DA, de Cabo R (2008) Resveratrol delays age-related deterioration and mimics transcriptional aspects of dietary restriction without extending life span. Cell Metab 8:157–168PubMedCentralPubMedGoogle Scholar
  135. 135.
    Xu Q, Hao X, Yang Q, Si L (2009) Resveratrol prevents hyperglycemia-induced endothelial dysfunction via activation of adenosine monophosphate-activated protein kinase. Biochem Biophys Res Commun 388:389–394PubMedGoogle Scholar
  136. 136.
    Klinge CM, Wickramasinghe NS, Ivanova MM, Dougherty SM (2008) Resveratrol stimulates nitric oxide production by increasing estrogen receptor alpha-Src-caveolin-1 interaction and phosphorylation in human umbilical vein endothelial cells. FASEB J 22:2185–2197PubMedGoogle Scholar
  137. 137.
    Mattagajasingh I, Kim CS, Naqvi A, Yamamori T, Hoffman TA, Jung SB, DeRicco J, Kasuno K, Irani K (2007) SIRT1 promotes endothelium-dependent vascular relaxation by activating endothelial nitric oxide synthase. Proc Natl Acad Sci USA 104:14855–14860PubMedCentralPubMedGoogle Scholar
  138. 138.
    Xia N, Strand S, Schlufter F, Siuda D, Reifenberg G, Kleinert H, Forstermann U, Li H (2013) Role of SIRT1 and FOXO factors in eNOS transcriptional activation by resveratrol. Nitric Oxide 32:29–35PubMedGoogle Scholar
  139. 139.
    Csiszar A, Labinskyy N, Pinto JT, Ballabh P, Zhang H, Losonczy G, Pearson K, de Cabo R, Pacher P, Zhang C, Ungvari Z (2009) Resveratrol induces mitochondrial biogenesis in endothelial cells. Am J Physiol Heart Circ Physiol 297:H13–H20PubMedCentralPubMedGoogle Scholar
  140. 140.
    Yang J, Wang N, Li J, Zhang J, Feng P (2010) Effects of resveratrol on NO secretion stimulated by insulin and its dependence on SIRT1 in high glucose cultured endothelial cells. Endocrine 37:365–372PubMedGoogle Scholar
  141. 141.
    Chen ZP, Mitchelhill KI, Michell BJ, Stapleton D, Rodriguez-Crespo I, Witters LA, Power DA, Ortiz de Montellano PR, Kemp BE (1999) AMP-activated protein kinase phosphorylation of endothelial NO synthase. FEBS Lett 443:285–289PubMedGoogle Scholar
  142. 142.
    Liu Z, Song Y, Zhang X, Liu Z, Zhang W, Mao W, Wang W, Cui W, Zhang X, Jia X, Li N, Han C, Liu C (2005) Effects of trans-resveratrol on hypertension-induced cardiac hypertrophy using the partially nephrectomized rat model. Clin Exp Pharmacol Physiol 32:1049–1054PubMedGoogle Scholar
  143. 143.
    Miyazaki R, Ichiki T, Hashimoto T, Inanaga K, Imayama I, Sadoshima J, Sunagawa K (2008) SIRT1, a longevity gene, downregulates angiotensin II type 1 receptor expression in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 28:1263–1269PubMedGoogle Scholar
  144. 144.
    Rivera L, Moron R, Zarzuelo A, Galisteo M (2009) Long-term resveratrol administration reduces metabolic disturbances and lowers blood pressure in obese Zucker rats. Biochem Pharmacol 77:1053–1063PubMedGoogle Scholar
  145. 145.
    Miatello R, Vazquez M, Renna N, Cruzado M, Zumino AP, Risler N (2005) Chronic administration of resveratrol prevents biochemical cardiovascular changes in fructose-fed rats. Am J Hypertens 18:864–870PubMedGoogle Scholar
  146. 146.
    Chan V, Fenning A, Iyer A, Hoey A, Brown L (2011) Resveratrol improves cardiovascular function in DOCA-salt hypertensive rats. Curr Pharm Biotechnol 12:429–436PubMedGoogle Scholar
  147. 147.
    Toklu HZ, Sehirli O, Ersahin M, Suleymanoglu S, Yiginer O, Emekli-Alturfan E, Yarat A, Yegen BC, Sener G (2010) Resveratrol improves cardiovascular function and reduces oxidative organ damage in the renal, cardiovascular and cerebral tissues of two-kidney, one-clip hypertensive rats. J Pharm Pharmacol 62:1784–1793PubMedGoogle Scholar
  148. 148.
    Csiszar A, Labinskyy N, Olson S, Pinto JT, Gupte S, Wu JM, Hu F, Ballabh P, Podlutsky A, Losonczy G, de Cabo R, Mathew R, Wolin MS, Ungvari Z (2009) Resveratrol prevents monocrotaline-induced pulmonary hypertension in rats. Hypertension 54:668–675PubMedCentralPubMedGoogle Scholar
  149. 149.
    Rush JW, Quadrilatero J, Levy AS, Ford RJ (2007) Chronic resveratrol enhances endothelium-dependent relaxation but does not alter eNOS levels in aorta of spontaneously hypertensive rats. Exp Biol Med (Maywood) 232:814–822Google Scholar
  150. 150.
    Thandapilly SJ, Wojciechowski P, Behbahani J, Louis XL, Yu L, Juric D, Kopilas MA, Anderson HD, Netticadan T (2010) Resveratrol prevents the development of pathological cardiac hypertrophy and contractile dysfunction in the SHR without lowering blood pressure. Am J Hypertens 23:192–196PubMedGoogle Scholar
  151. 151.
    Dolinsky VW, Chan AY, Robillard Frayne I, Light PE, Des Rosiers C, Dyck JR (2009) Resveratrol prevents the prohypertrophic effects of oxidative stress on LKB1. Circulation 119:1643–1652PubMedGoogle Scholar
  152. 152.
    Mizutani K, Ikeda K, Kawai Y, Yamori Y (2001) Protective effect of resveratrol on oxidative damage in male and female stroke-prone spontaneously hypertensive rats. Clin Exp Pharmacol Physiol 28:55–59PubMedGoogle Scholar
  153. 153.
    Dolinsky VW, Chakrabarti S, Pereira TJ, Oka T, Levasseur J, Beker D, Zordoky BN, Morton JS, Nagendran J, Lopaschuk GD, Davidge ST, Dyck JR (2013) Resveratrol prevents hypertension and cardiac hypertrophy in hypertensive rats and mice. Biochim Biophys Acta 1832:1723–1733PubMedGoogle Scholar
  154. 154.
    Thandapilly SJ, Louis XL, Yang T, Stringer DM, Yu L, Zhang S, Wigle J, Kardami E, Zahradka P, Taylor C, Anderson HD, Netticadan T (2011) Resveratrol prevents norepinephrine induced hypertrophy in adult rat cardiomyocytes, by activating NO-AMPK pathway. Eur J Pharmacol 668:217–224PubMedGoogle Scholar
  155. 155.
    Robich MP, Chu LM, Chaudray M, Nezafat R, Han Y, Clements RT, Laham RJ, Manning WJ, Coady MA, Sellke FW (2010) Anti-angiogenic effect of high-dose resveratrol in a swine model of metabolic syndrome. Surgery 148:453–462PubMedCentralPubMedGoogle Scholar
  156. 156.
    Mattison JA, Wang M, Bernier M, Zhang J, Park SS, Maudsley S, An SS, Santhanam L, Martin B, Faulkner S, Morrell C, Baur JA, Peshkin L, Sosnowska D, Csiszar A, Herbert RL, Tilmont EM, Ungvari Z, Pearson KJ, Lakatta EG, de Cabo R (2014) Resveratrol prevents high fat/sucrose diet-induced central arterial wall inflammation and stiffening in nonhuman primates. Cell Metab 20:183–190PubMedGoogle Scholar
  157. 157.
    Hung LM, Chen JK, Huang SS, Lee RS, Su MJ (2000) Cardioprotective effect of resveratrol, a natural antioxidant derived from grapes. Cardiovasc Res 47:549–555PubMedGoogle Scholar
  158. 158.
    Spanier G, Xu H, Xia N, Tobias S, Deng S, Wojnowski L, Forstermann U, Li H (2009) Resveratrol reduces endothelial oxidative stress by modulating the gene expression of superoxide dismutase 1 (SOD1), glutathione peroxidase 1 (GPx1) and NADPH oxidase subunit (Nox4). J Physiol Pharmacol 60(Suppl 4):111–116PubMedGoogle Scholar
  159. 159.
    Kim JW, Lim SC, Lee MY, Lee JW, Oh WK, Kim SK, Kang KW (2010) Inhibition of neointimal formation by trans-resveratrol: role of phosphatidyl inositol 3-kinase-dependent Nrf2 activation in heme oxygenase-1 induction. Mol Nutr Food Res 54:1497–1505PubMedGoogle Scholar
  160. 160.
    Ungvari Z, Orosz Z, Rivera A, Labinskyy N, Zhao X, Olson S, Podlutsky A, Csiszar A (2007) Resveratrol increases vascular oxidative stress resistance. Am J Physiol Heart Circ Physiol 292:H2417–H2424PubMedGoogle Scholar
  161. 161.
    Xia N, Daiber A, Habermeier A, Closs EI, Thum T, Spanier G, Lu Q, Oelze M, Torzewski M, Lackner KJ, Munzel T, Forstermann U, Li H (2010) Resveratrol reverses endothelial nitric-oxide synthase uncoupling in apolipoprotein E knockout mice. J Pharmacol Exp Ther 335:149–154PubMedGoogle Scholar
  162. 162.
    Kaneko H, Anzai T, Morisawa M, Kohno T, Nagai T, Anzai A, Takahashi T, Shimoda M, Sasaki A, Maekawa Y, Yoshimura K, Aoki H, Tsubota K, Yoshikawa T, Okada Y, Ogawa S, Fukuda K (2011) Resveratrol prevents the development of abdominal aortic aneurysm through attenuation of inflammation, oxidative stress, and neovascularization. Atherosclerosis 217:350–357PubMedGoogle Scholar
  163. 163.
    Tanno M, Kuno A, Yano T, Miura T, Hisahara S, Ishikawa S, Shimamoto K, Horio Y (2010) Induction of manganese superoxide dismutase by nuclear translocation and activation of SIRT1 promotes cell survival in chronic heart failure. J Biol Chem 285:8375–8382PubMedCentralPubMedGoogle Scholar
  164. 164.
    Ungvari Z, Bagi Z, Feher A, Recchia FA, Sonntag WE, Pearson K, de Cabo R, Csiszar A (2010) Resveratrol confers endothelial protection via activation of the antioxidant transcription factor Nrf2. Am J Physiol Heart Circ Physiol 299:H18–H24PubMedCentralPubMedGoogle Scholar
  165. 165.
    Chow SE, Hshu YC, Wang JS (1985) Chen JK (2007) Resveratrol attenuates oxLDL-stimulated NADPH oxidase activity and protects endothelial cells from oxidative functional damages. J Appl Physiol 102:1520–1527Google Scholar
  166. 166.
    Zhang H, Zhang J, Ungvari Z, Zhang C (2009) Resveratrol improves endothelial function: role of TNF{alpha} and vascular oxidative stress. Arterioscler Thromb Vasc Biol 29:1164–1171PubMedCentralPubMedGoogle Scholar
  167. 167.
    Toth P, Tarantini S, Tucsek Z, Ashpole NM, Sosnowska D, Gautam T, Ballabh P, Koller A, Sonntag WE, Csiszar A, Ungvari Z (2014) Resveratrol treatment rescues neurovascular coupling in aged mice: role of improved cerebromicrovascular endothelial function and downregulation of NADPH oxidase. Am J Physiol Heart Circ Physiol 306:H299–H308PubMedCentralPubMedGoogle Scholar
  168. 168.
    Csiszar A, Labinskyy N, Orosz Z, Ungvari Z (2006) Altered mitochondrial energy metabolism may play a role in vascular aging. Med Hypotheses 67:904–908PubMedGoogle Scholar
  169. 169.
    Ungvari Z, Labinskyy N, Gupte S, Chander PN, Edwards JG, Csiszar A (2008) Dysregulation of mitochondrial biogenesis in vascular endothelial and smooth muscle cells of aged rats. Am J Physiol Heart Circ Physiol 294:H2121–H2128PubMedGoogle Scholar
  170. 170.
    Ungvari Z, Labinskyy N, Mukhopadhyay P, Pinto JT, Bagi Z, Ballabh P, Zhang C, Pacher P, Csiszar A (2009) Resveratrol attenuates mitochondrial oxidative stress in coronary arterial endothelial cells. Am J Physiol Heart Circ Physiol 297:H1876–H1881PubMedCentralPubMedGoogle Scholar
  171. 171.
    Frankel EN, Waterhouse AL, Kinsella JE (1993) Inhibition of human LDL oxidation by resveratrol. Lancet 341:1103–1104PubMedGoogle Scholar
  172. 172.
    Wang MJ, Huang HM, Hsieh SJ, Jeng KC, Kuo JS (2001) Resveratrol inhibits interleukin-6 production in cortical mixed glial cells under hypoxia/hypoglycemia followed by reoxygenation. J Neuroimmunol 112:28–34PubMedGoogle Scholar
  173. 173.
    Culpitt SV, Rogers DF, Fenwick PS, Shah P, De Matos C, Russell RE, Barnes PJ, Donnelly LE (2003) Inhibition by red wine extract, resveratrol, of cytokine release by alveolar macrophages in COPD. Thorax 58:942–946PubMedCentralPubMedGoogle Scholar
  174. 174.
    Goh SS, Woodman OL, Pepe S, Cao AH, Qin C, Ritchie RH (2007) The red wine antioxidant resveratrol prevents cardiomyocyte injury following ischemia-reperfusion via multiple sites and mechanisms. Antioxid Redox Signal 9:101–113PubMedGoogle Scholar
  175. 175.
    Marambaud P, Zhao H, Davies P (2005) Resveratrol promotes clearance of Alzheimer’s disease amyloid-beta peptides. J Biol Chem 280:37377–37382PubMedGoogle Scholar
  176. 176.
    Karuppagounder SS, Pinto JT, Xu H, Chen HL, Beal MF, Gibson GE (2009) Dietary supplementation with resveratrol reduces plaque pathology in a transgenic model of Alzheimer’s disease. Neurochem Int 54:111–118PubMedCentralPubMedGoogle Scholar
  177. 177.
    Albani D, Polito L, Forloni G (2010) Sirtuins as novel targets for Alzheimer’s disease and other neurodegenerative disorders: experimental and genetic evidence. J Alzheimers Dis 19:11–26PubMedGoogle Scholar
  178. 178.
    Lee HR, Shin HK, Park SY, Kim HY, Lee WS, Rhim BY, Hong KW, Kim CD (2014) Cilostazol suppresses beta-amyloid production by activating a disintegrin and metalloproteinase 10 via the upregulation of SIRT1-coupled retinoic acid receptor-beta. J Neurosci Res 92:1581–1590PubMedGoogle Scholar
  179. 179.
    Capiralla H, Vingtdeux V, Zhao H, Sankowski R, Al-Abed Y, Davies P, Marambaud P (2012) Resveratrol mitigates lipopolysaccharide- and A ss-mediated microglial inflammation by inhibiting the TLR4/NF-κB/STAT signaling cascade. J Neurochem 120:461–472PubMedCentralPubMedGoogle Scholar
  180. 180.
    Mudo G, Makela J, Di Liberto V, Tselykh TV, Olivieri M, Piepponen P, Eriksson O, Malkia A, Bonomo A, Kairisalo M, Aguirre JA, Korhonen L, Belluardo N, Lindholm D (2012) Transgenic expression and activation of PGC-1 alpha protect dopaminergic neurons in the MPTP mouse model of Parkinson’s disease. Cell Mol Life Sci 69:1153–1165PubMedGoogle Scholar
  181. 181.
    Ferretta A, Gaballo A, Tanzarella P, Piccoli C, Capitanio N, Nico B, Annese T, Di Paola M, Dell’aquila C, De Mari M, Ferranini E, Bonifati V, Pacelli C, Cocco T (2014) Effect of resveratrol on mitochondrial function: Implications in parkin-associated familiar Parkinson’s disease. Biochim Biophys ActaGoogle Scholar
  182. 182.
    Gerhardt E, Graber S, Szego EM, Moisoi N, Martins LM, Outeiro TF, Kermer P (2011) Idebenone and resveratrol extend lifespan and improve motor function of HtrA2 knockout mice. PLoS One 6:e28855PubMedCentralPubMedGoogle Scholar
  183. 183.
    Shindler KS, Ventura E, Rex TS, Elliott P, Rostami A (2007) SIRT1 activation confers neuroprotection in experimental optic neuritis. Invest Ophthalmol Vis Sci 48:3602–3609PubMedCentralPubMedGoogle Scholar
  184. 184.
    Calliari A, Bobba N, Escande C, Chini EN (2014) Resveratrol delays Wallerian degeneration in a NAD(+) and DBC1 dependent manner. Exp Neurol 251:91–100PubMedGoogle Scholar
  185. 185.
    Renaud S, Delorgeril M (1992) Wine, alcohol, platelets, and the french paradox for coronary heart-disease. Lancet 339:1523–1526PubMedGoogle Scholar
  186. 186.
    Goldberg DM, Yan J, Soleas GJ (2003) Absorption of three wine-related polyphenols in three different matrices by healthy subjects. Clin Biochem 36:79–87PubMedGoogle Scholar
  187. 187.
    Semba RD, Ferrucci L, Bartali B, Urpi-Sarda M, Zamora-Ros R, Sun K, Cherubini A, Bandinelli S, Andres-Lacueva C (2014) Resveratrol levels and all-cause mortality in older community-dwelling adults. JAMA Intern Med 174:1077–1084PubMedGoogle Scholar
  188. 188.
    Meng X, Maliakal P, Lu H, Lee MJ, Yang CS (2004) Urinary and plasma levels of resveratrol and quercetin in humans, mice, and rats after ingestion of pure compounds and grape juice. J Agric Food Chem 52:935–942PubMedGoogle Scholar
  189. 189.
    Baur JA, Sinclair DA (2006) Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discovery 5:493–506Google Scholar
  190. 190.
    Vihko V, Hirsimaki Y, Ajiduah AO (1978) beta-Glucuronidase activity in trained red and white skeletal muscle of mice. Eur J Appl Physiol Occup Physiol 39:255–261PubMedGoogle Scholar
  191. 191.
    Campbell JE, Drucker DJ (2013) Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab 17:819–837PubMedGoogle Scholar
  192. 192.
    Ong WK, Gribble FM, Reimann F, Lynch MJ, Houslay MD, Baillie GS, Furman BL, Pyne NJ (2009) The role of the PDE4D cAMP phosphodiesterase in the regulation of glucagon-like peptide-1 release. Br J Pharmacol 157:633–644PubMedCentralPubMedGoogle Scholar
  193. 193.
    Dao TM, Waget A, Klopp P, Serino M, Vachoux C, Pechere L, Drucker DJ, Champion S, Barthelemy S, Barra Y, Burcelin R, Seree E (2011) Resveratrol increases glucose induced GLP-1 secretion in mice: a mechanism which contributes to the glycemic control. PLoS One 6:e20700PubMedCentralPubMedGoogle Scholar
  194. 194.
    Boocock DJ, Faust GE, Patel KR, Schinas AM, Brown VA, Ducharme MP, Booth TD, Crowell JA, Perloff M, Gescher AJ, Steward WP, Brenner DE (2007) Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. Cancer Epidemiol Biomarkers Prev 16:1246–1252PubMedGoogle Scholar
  195. 195.
    Brown VA, Patel KR, Viskaduraki M, Crowell JA, Perloff M, Booth TD, Vasilinin G, Sen A, Schinas AM, Piccirilli G, Brown K, Steward WP, Gescher AJ, Brenner DE (2010) Repeat dose study of the cancer chemopreventive agent resveratrol in healthy volunteers: safety, pharmacokinetics, and effect on the insulin-like growth factor axis. Cancer Res 70:9003–9011PubMedCentralPubMedGoogle Scholar
  196. 196.
    Almeida L, Vaz-da-Silva M, Falcao A, Soares E, Costa R, Loureiro AI, Fernandes-Lopes C, Rocha JF, Nunes T, Wright L, Soares-da-Silva P (2009) Pharmacokinetic and safety profile of trans-resveratrol in a rising multiple-dose study in healthy volunteers. Mol Nutr Food Res 53(Suppl 1):S7–S15PubMedGoogle Scholar
  197. 197.
    Chow HH, Garland LL, Hsu CH, Vining DR, Chew WM, Miller JA, Perloff M, Crowell JA, Alberts DS (2010) Resveratrol modulates drug- and carcinogen-metabolizing enzymes in a healthy volunteer study. Cancer Prev Res (Phila) 3:1168–1175Google Scholar
  198. 198.
    Brasnyo P, Molnar GA, Mohas M, Marko L, Laczy B, Cseh J, Mikolas E, Szijarto IA, Merei A, Halmai R, Meszaros LG, Suemegi B, Wittmann I (2011) Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients. Br J Nutr 106:383–389PubMedGoogle Scholar
  199. 199.
    Fujitaka K, Otani H, Jo F, Jo H, Nomura E, Iwasaki M, Nishikawa M, Iwasaka T, Das DK (2011) Modified resveratrol Longevinex improves endothelial function in adults with metabolic syndrome receiving standard treatment. Nutr Res 31:842–847PubMedGoogle Scholar
  200. 200.
    Bhatt JK, Thomas S, Nanjan MJ (2012) Resveratrol supplementation improves glycemic control in type 2 diabetes mellitus. Nutr Res 32:537–541PubMedGoogle Scholar
  201. 201.
    Tome-Carneiro J, Gonzalvez M, Larrosa M, Yanez-Gascon MJ, Garcia-Almagro FJ, Ruiz-Ros JA, Tomas-Barberan FA, Garcia-Conesa MT, Espin JC (2013) Grape resveratrol increases serum adiponectin and downregulates inflammatory genes in peripheral blood mononuclear cells: a triple-blind, placebo-controlled, one-year clinical trial in patients with stable coronary artery disease. Cardiovasc Drugs Ther 27:37–48PubMedCentralPubMedGoogle Scholar
  202. 202.
    Tome-Carneiro J, Gonzalvez M, Larrosa M, Yanez-Gascon MJ, Garcia-Almagro FJ, Ruiz-Ros JA, Garcia-Conesa MT, Tomas-Barberan FA, Espin JC (2012) One-year consumption of a grape nutraceutical containing resveratrol improves the inflammatory and fibrinolytic status of patients in primary prevention of cardiovascular disease. Am J Cardiol 110:356–363PubMedGoogle Scholar
  203. 203.
    Wong YT, Gruber J, Jenner AM, Tay FE, Ruan R (2011) Chronic resveratrol intake reverses pro-inflammatory cytokine profile and oxidative DNA damage in ageing hybrid mice. Age (Dordr) 33:229–246Google Scholar
  204. 204.
    Magyar K, Halmosi R, Palfi A, Feher G, Czopf L, Fulop A, Battyany I, Sumegi B, Toth K, Szabados E (2012) Cardioprotection by resveratrol: a human clinical trial in patients with stable coronary artery disease. Clinical Hemorheol Microcirc 50:179–187Google Scholar
  205. 205.
    Crandall JP, Oram V, Trandafirescu G, Reid M, Kishore P, Hawkins M, Cohen HW, Barzilai N (2012) Pilot study of resveratrol in older adults with impaired glucose tolerance. J Gerontol A Biol Sci Med Sci 67:1307–1312PubMedCentralPubMedGoogle Scholar
  206. 206.
    Ghanim H, Sia CL, Abuaysheh S, Korzeniewski K, Patnaik P, Marumganti A, Chaudhuri A, Dandona P (2010) An antiinflammatory and reactive oxygen species suppressive effects of an extract of Polygonum cuspidatum containing resveratrol. J Clin Endocrinol Metab 95:E1–E8PubMedCentralPubMedGoogle Scholar
  207. 207.
    Chachay VS, Macdonald GA, Martin JH, Whitehead JP, O’Moore-Sullivan TM, Lee P, Franklin M, Klein K, Taylor PJ, Ferguson M, Coombes JS, Thomas GP, Cowin GJ, Kirkpatrick CM, Prins JB, Hickman IJ (2014) Resveratrol does not benefit patients with non-alcoholic fatty liver disease. Clin Gastroenterol HepatolGoogle Scholar
  208. 208.
    Timmers S, Konings E, Bilet L, Houtkooper RH, van de Weijer T, Goossens GH, Hoeks J, van der Krieken S, Ryu D, Kersten S, Moonen-Kornips E, Hesselink MKC, Kunz I, Schrauwen-Hinderling VB, Blaak EE, Auwerx J, Schrauwen P (2011) Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metab 14:612–622PubMedGoogle Scholar
  209. 209.
    Konings E, Timmers S, Boekschoten MV, Goossens GH, Jocken JW, Afman LA, Muller M, Schrauwen P, Mariman EC, Blaak EE (2014) The effects of 30 days resveratrol supplementation on adipose tissue morphology and gene expression patterns in obese men. Int J Obes (Lond) 38:470–473Google Scholar
  210. 210.
    Yoshino J, Conte C, Fontana L, Mittendorfer B, Imai S, Schechtman KB, Gu C, Kunz I, Rossi Fanelli F, Patterson BW, Klein S (2012) Resveratrol supplementation does not improve metabolic function in nonobese women with normal glucose tolerance. Cell Metab 16:658–664PubMedCentralPubMedGoogle Scholar
  211. 211.
    Poulsen MM, Vestergaard PF, Clasen BF, Radko Y, Christensen LP, Stodkilde-Jorgensen H, Moller N, Jessen N, Pedersen SB, Jorgensen JO (2013) High-dose resveratrol supplementation in obese men: an investigator-initiated, randomized, placebo-controlled clinical trial of substrate metabolism, insulin sensitivity, and body composition. Diabetes 62:1186–1195PubMedCentralPubMedGoogle Scholar
  212. 212.
    Hubbard BP, Sinclair DA (2014) Small molecule SIRT1 activators for the treatment of aging and age-related diseases. Trends Pharmacol Sci 35:146–154PubMedCentralPubMedGoogle Scholar
  213. 213.
    Gomes AP, Price NL, Ling AJ, Moslehi JJ, Montgomery MK, Rajman L, White JP, Teodoro JS, Wrann CD, Hubbard BP, Mercken EM, Palmeira CM, de Cabo R, Rolo AP, Turner N, Bell EL, Sinclair DA (2013) Declining NAD(+) induces a pseudohypoxic state disrupting nuclear-mitochondrial communication during aging. Cell 155:1624–1638PubMedCentralPubMedGoogle Scholar
  214. 214.
    Canto C, Houtkooper RH, Pirinen E, Youn DY, Oosterveer MH, Cen Y, Fernandez-Marcos PJ, Yamamoto H, Andreux PA, Cettour-Rose P, Gademann K, Rinsch C, Schoonjans K, Sauve AA, Auwerx J (2012) The NAD(+) precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity. Cell Metab 15:838–847PubMedCentralPubMedGoogle Scholar
  215. 215.
    Cerutti R, Pirinen E, Lamperti C, Marchet S, Sauve AA, Li W, Leoni V, Schon EA, Dantzer F, Auwerx J, Viscomi C, Zeviani M (2014) NAD(+)-dependent activation of Sirt1 corrects the phenotype in a mouse model of mitochondrial disease. Cell Metab 19:1042–1049PubMedCentralPubMedGoogle Scholar
  216. 216.
    Mouchiroud L, Houtkooper RH, Moullan N, Katsyuba E, Ryu D, Canto C, Mottis A, Jo YS, Viswanathan M, Schoonjans K, Guarente L, Auwerx J (2013) The NAD(+)/sirtuin pathway modulates longevity through activation of mitochondrial UPR and FOXO signaling. Cell 154:430–441PubMedCentralPubMedGoogle Scholar
  217. 217.
    Wouters EF, Bredenbroker D, Teichmann P, Brose M, Rabe KF, Fabbri LM, Goke B (2012) Effect of the phosphodiesterase 4 inhibitor roflumilast on glucose metabolism in patients with treatment-naive, newly diagnosed type 2 diabetes mellitus. J Clin Endocrinol Metab 97:E1720–E1725PubMedGoogle Scholar

Copyright information

© Springer Basel (outside the USA) 2014

Authors and Affiliations

  1. 1.Laboratory of Obesity and Aging Research, Genetics and Developmental Biology Center, National Heart Lung and Blood InstituteNational Institutes of HealthBethesdaUSA

Personalised recommendations